Report Detail
Global Trivalent Inactivated Influenza Vaccine Market Growth 2022-2028
- RnM4489218 |
- 01 September, 2022 |
- Global |
- 98 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
The global market for Trivalent Inactivated Influenza Vaccine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Trivalent Inactivated Influenza Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Trivalent Inactivated Influenza Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Trivalent Inactivated Influenza Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Trivalent Inactivated Influenza Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Trivalent Inactivated Influenza Vaccine players cover AstraZeneca, Sanofi S.A, Abbott, GlaxoSmithKline and Merck, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Trivalent Inactivated Influenza Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Trivalent Inactivated Influenza Vaccine market, with both quantitative and qualitative data, to help readers understand how the Trivalent Inactivated Influenza Vaccine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Doses.
Market Segmentation:
The study segments the Trivalent Inactivated Influenza Vaccine market and forecasts the market size by Type (Nasal Spray, Intramuscular Injection and Intradermal Injection), by Application (Hospital, Clinic, Public Health Agency and Others), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Nasal Spray
Intramuscular Injection
Intradermal Injection
Segmentation by application
Hospital
Clinic
Public Health Agency
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
AstraZeneca
Sanofi S.A
Abbott
GlaxoSmithKline
Merck
Novartis
Pfizer
Serum Institute of India
CSL Limited
Chapter Introduction
Chapter 1: Scope of Trivalent Inactivated Influenza Vaccine, Research Methodology, etc.
Chapter 2: Executive Summary, global Trivalent Inactivated Influenza Vaccine market size (sales and revenue) and CAGR, Trivalent Inactivated Influenza Vaccine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Trivalent Inactivated Influenza Vaccine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Trivalent Inactivated Influenza Vaccine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Trivalent Inactivated Influenza Vaccine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including AstraZeneca, Sanofi S.A, Abbott, GlaxoSmithKline, Merck, Novartis, Pfizer, Serum Institute of India and CSL Limited, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Trivalent Inactivated Influenza Vaccine Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Trivalent Inactivated Influenza Vaccine by Geographic Region, 2017, 2022 & 2028
- 2.1.3 World Current & Future Analysis for Trivalent Inactivated Influenza Vaccine by Country/Region, 2017, 2022 & 2028
- 2.2 Trivalent Inactivated Influenza Vaccine Segment by Type
- 2.2.1 Nasal Spray
- 2.2.2 Intramuscular Injection
- 2.2.3 Intradermal Injection
- 2.3 Trivalent Inactivated Influenza Vaccine Sales by Type
- 2.3.1 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2017-2022)
- 2.3.2 Global Trivalent Inactivated Influenza Vaccine Revenue and Market Share by Type (2017-2022)
- 2.3.3 Global Trivalent Inactivated Influenza Vaccine Sale Price by Type (2017-2022)
- 2.4 Trivalent Inactivated Influenza Vaccine Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.4.3 Public Health Agency
- 2.4.4 Others
- 2.5 Trivalent Inactivated Influenza Vaccine Sales by Application
- 2.5.1 Global Trivalent Inactivated Influenza Vaccine Sale Market Share by Application (2017-2022)
- 2.5.2 Global Trivalent Inactivated Influenza Vaccine Revenue and Market Share by Application (2017-2022)
- 2.5.3 Global Trivalent Inactivated Influenza Vaccine Sale Price by Application (2017-2022)
3 Global Trivalent Inactivated Influenza Vaccine by Company
- 3.1 Global Trivalent Inactivated Influenza Vaccine Breakdown Data by Company
- 3.1.1 Global Trivalent Inactivated Influenza Vaccine Annual Sales by Company (2020-2022)
- 3.1.2 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Company (2020-2022)
- 3.2 Global Trivalent Inactivated Influenza Vaccine Annual Revenue by Company (2020-2022)
- 3.2.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Company (2020-2022)
- 3.2.2 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Company (2020-2022)
- 3.3 Global Trivalent Inactivated Influenza Vaccine Sale Price by Company
- 3.4 Key Manufacturers Trivalent Inactivated Influenza Vaccine Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Trivalent Inactivated Influenza Vaccine Product Location Distribution
- 3.4.2 Players Trivalent Inactivated Influenza Vaccine Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Trivalent Inactivated Influenza Vaccine by Geographic Region
- 4.1 World Historic Trivalent Inactivated Influenza Vaccine Market Size by Geographic Region (2017-2022)
- 4.1.1 Global Trivalent Inactivated Influenza Vaccine Annual Sales by Geographic Region (2017-2022)
- 4.1.2 Global Trivalent Inactivated Influenza Vaccine Annual Revenue by Geographic Region
- 4.2 World Historic Trivalent Inactivated Influenza Vaccine Market Size by Country/Region (2017-2022)
- 4.2.1 Global Trivalent Inactivated Influenza Vaccine Annual Sales by Country/Region (2017-2022)
- 4.2.2 Global Trivalent Inactivated Influenza Vaccine Annual Revenue by Country/Region
- 4.3 Americas Trivalent Inactivated Influenza Vaccine Sales Growth
- 4.4 APAC Trivalent Inactivated Influenza Vaccine Sales Growth
- 4.5 Europe Trivalent Inactivated Influenza Vaccine Sales Growth
- 4.6 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Growth
5 Americas
- 5.1 Americas Trivalent Inactivated Influenza Vaccine Sales by Country
- 5.1.1 Americas Trivalent Inactivated Influenza Vaccine Sales by Country (2017-2022)
- 5.1.2 Americas Trivalent Inactivated Influenza Vaccine Revenue by Country (2017-2022)
- 5.2 Americas Trivalent Inactivated Influenza Vaccine Sales by Type
- 5.3 Americas Trivalent Inactivated Influenza Vaccine Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Trivalent Inactivated Influenza Vaccine Sales by Region
- 6.1.1 APAC Trivalent Inactivated Influenza Vaccine Sales by Region (2017-2022)
- 6.1.2 APAC Trivalent Inactivated Influenza Vaccine Revenue by Region (2017-2022)
- 6.2 APAC Trivalent Inactivated Influenza Vaccine Sales by Type
- 6.3 APAC Trivalent Inactivated Influenza Vaccine Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
7 Europe
- 7.1 Europe Trivalent Inactivated Influenza Vaccine by Country
- 7.1.1 Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2017-2022)
- 7.1.2 Europe Trivalent Inactivated Influenza Vaccine Revenue by Country (2017-2022)
- 7.2 Europe Trivalent Inactivated Influenza Vaccine Sales by Type
- 7.3 Europe Trivalent Inactivated Influenza Vaccine Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Trivalent Inactivated Influenza Vaccine by Country
- 8.1.1 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2017-2022)
- 8.1.2 Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue by Country (2017-2022)
- 8.2 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Type
- 8.3 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Trivalent Inactivated Influenza Vaccine
- 10.3 Manufacturing Process Analysis of Trivalent Inactivated Influenza Vaccine
- 10.4 Industry Chain Structure of Trivalent Inactivated Influenza Vaccine
11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Trivalent Inactivated Influenza Vaccine Distributors
- 11.3 Trivalent Inactivated Influenza Vaccine Customer
12 World Forecast Review for Trivalent Inactivated Influenza Vaccine by Geographic Region
- 12.1 Global Trivalent Inactivated Influenza Vaccine Market Size Forecast by Region
- 12.1.1 Global Trivalent Inactivated Influenza Vaccine Forecast by Region (2023-2028)
- 12.1.2 Global Trivalent Inactivated Influenza Vaccine Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Trivalent Inactivated Influenza Vaccine Forecast by Type
- 12.7 Global Trivalent Inactivated Influenza Vaccine Forecast by Application
13 Key Players Analysis
- 13.1 AstraZeneca
- 13.1.1 AstraZeneca Company Information
- 13.1.2 AstraZeneca Trivalent Inactivated Influenza Vaccine Product Offered
- 13.1.3 AstraZeneca Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.1.4 AstraZeneca Main Business Overview
- 13.1.5 AstraZeneca Latest Developments
- 13.2 Sanofi S.A
- 13.2.1 Sanofi S.A Company Information
- 13.2.2 Sanofi S.A Trivalent Inactivated Influenza Vaccine Product Offered
- 13.2.3 Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.2.4 Sanofi S.A Main Business Overview
- 13.2.5 Sanofi S.A Latest Developments
- 13.3 Abbott
- 13.3.1 Abbott Company Information
- 13.3.2 Abbott Trivalent Inactivated Influenza Vaccine Product Offered
- 13.3.3 Abbott Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.3.4 Abbott Main Business Overview
- 13.3.5 Abbott Latest Developments
- 13.4 GlaxoSmithKline
- 13.4.1 GlaxoSmithKline Company Information
- 13.4.2 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product Offered
- 13.4.3 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.4.4 GlaxoSmithKline Main Business Overview
- 13.4.5 GlaxoSmithKline Latest Developments
- 13.5 Merck
- 13.5.1 Merck Company Information
- 13.5.2 Merck Trivalent Inactivated Influenza Vaccine Product Offered
- 13.5.3 Merck Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.5.4 Merck Main Business Overview
- 13.5.5 Merck Latest Developments
- 13.6 Novartis
- 13.6.1 Novartis Company Information
- 13.6.2 Novartis Trivalent Inactivated Influenza Vaccine Product Offered
- 13.6.3 Novartis Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.6.4 Novartis Main Business Overview
- 13.6.5 Novartis Latest Developments
- 13.7 Pfizer
- 13.7.1 Pfizer Company Information
- 13.7.2 Pfizer Trivalent Inactivated Influenza Vaccine Product Offered
- 13.7.3 Pfizer Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.7.4 Pfizer Main Business Overview
- 13.7.5 Pfizer Latest Developments
- 13.8 Serum Institute of India
- 13.8.1 Serum Institute of India Company Information
- 13.8.2 Serum Institute of India Trivalent Inactivated Influenza Vaccine Product Offered
- 13.8.3 Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.8.4 Serum Institute of India Main Business Overview
- 13.8.5 Serum Institute of India Latest Developments
- 13.9 CSL Limited
- 13.9.1 CSL Limited Company Information
- 13.9.2 CSL Limited Trivalent Inactivated Influenza Vaccine Product Offered
- 13.9.3 CSL Limited Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.9.4 CSL Limited Main Business Overview
- 13.9.5 CSL Limited Latest Developments
14 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Trivalent Inactivated Influenza Vaccine. Industry analysis & Market Report on Trivalent Inactivated Influenza Vaccine is a syndicated market report, published as Global Trivalent Inactivated Influenza Vaccine Market Growth 2022-2028. It is complete Research Study and Industry Analysis of Trivalent Inactivated Influenza Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
